Retinal vein occlusion (RVO) is one of the most common causes of retinal vascular disease, second only to diabetic retinopathy in population-based studies. If left untreated, RVO can result in permanent vision impairment or blindness. Early recognition and prompt treatment are key to preserving vision and achieving good outcomes. In this article we review the epidemiology, risk factors, and clinical features of RVO.

**Epidemiology: Not So Definitive**

A recent pooled analysis of patients in the United States, Europe, Asia, and Australia estimated an overall prevalence of 16.4 million adults with RVO. Of these individuals, 2.5 million have central RVO (CRVO) and 13.9 million have branch RVO (BRVO). Incidence of RVO increases with age, with more than half of all cases occurring in patients older than 65 years. The Blue Mountain Eye Study showed a 0.7% incidence in patients younger than 60 years, increasing to 4.6% in patients 80 years and older.

Multiple studies have suggested that men may be at increased risk of CRVO compared with women, although this has been inconsistently demonstrated. There are also inconsistent reports regarding differences in ethnic predisposition to CRVO, with one recent longitudinal analysis finding a 58% increased risk in black patients compared with white patients after adjusting for common risk factors. Other studies have found that prevalence of any type of RVO was similar across races.

**Risk Factors, Protective Factors**

Associations have been demonstrated between RVO and certain systemic vascular risk factors, including hypertension, hyperlipidemia, diabetes with end organ damage, active smoking, and peripheral vascular disease (Figure 1). Of these systemic risk factors, one meta-analysis found that 47.9% of RVO cases were attributed to hypertension, 20.1% to hyperlipidemia, and 4.9% to diabetes mellitus. The researchers concluded that hypertension and hyperlipidemia were common risk factors for all forms of RVO in adults, whereas diabetes mellitus was less significant due to its inconsistent association with BRVO. Some studies have found increased risk of cerebrovascular and cardiovascular disease in patients with RVO, including a greater risk of developing acute myocardial infarction after a diagnosis of RVO, although other studies have shown similar rates of stroke and myocardial infarction regardless of RVO status.

Systemic factors protective against BRVO include increased high density lipoprotein level, moderate alcohol consumption, and increased physical activity. Only past physical activity has been shown to protect against CRVO.

Controversy exists regarding hypercoagulable states and risk of RVO. In one meta-analysis of 26 studies examining thrombophilic risk factors, hyperhomocysteinemia and anticardiolipin antibodies were significantly independently associated with RVO, with odds ratios of 8.9 (95% CI, 5.7-13.7) and 3.9 (95% CI, 2.3-6.70), respectively. Other reported associations include deficiency in proteins C and S, high alpha-2 globulin concentrations, higher activated factor VII concentrations, oral contraception use, and increased blood viscosity, although other studies have found no association.
Even in young patients, common vascular risk factors for RVO should initially be ruled out with routine studies, including blood pressure, intraocular pressure (IOP) measurement, complete blood count, glucose levels, and a lipid panel. If these studies are negative, or if a patient presents with bilateral RVO, recurrent RVO, or has a strong personal or family history of thrombosis, then testing for a range of thrombophilia can be considered in addition to ruling out any underlying systemic condition such as leukemia.

Ocular examination findings associated with RVO include elevated ocular perfusion pressure and arteriovenous nicking with focal arteriolar narrowing. Open-angle glaucoma is a well-recognized ocular comorbidity in patients with RVO. Optic nerve appearance and IOP should be noted to rule out concomitant glaucoma in patients diagnosed with RVO given the strong ophthalmic association.

CLINICAL FEATURES

Acute RVO commonly presents with painless visual disturbances. Ophthalmoscopic examination findings include varying degrees of dilated and tortuous retinal veins, intraretinal hemorrhages, retinal edema, exudates, and cotton wool spots. Chronic vein occlusion can be difficult to identify on clinical examination; it is suggested by venous collateral formation and vascular sheathing. In both acute and chronic RVO, fluorescein angiography (FA) can be used to assess for retinal ischemia, delayed retinal vein filling, and the presence of retinal neovascularization with fluorescein leakage.

CLASSIFICATION

RVO is classified based on anatomic location and degree of retinal ischemia. BRVO occurs in one retinal quadrant drained by a branch of the central retinal vein. CRVO occurs at or posterior to the lamina cribrosa and can result in four quadrants of retinal hemorrhages (Figure 2). Hemiretinal vein occlusions are the rarest variant; these occur when a major branch of the central retinal vein becomes occluded at or near the optic nerve or due to an anatomic variant in which the superior and inferior venous trunks merge posterior to the lamina cribrosa. If only one branch is occluded, one hemifield of the retina will be affected, and the other will remain relatively spared. According to the Central Vein Occlusion Study (CVOS), these subtypes can be further classified as ischemic if FA reveals greater than 10 disc diameters of retinal capillary nonperfusion, as perfused if fewer than 10 disc diameters of ischemia are present, or as indeterminate if an accurate determination of the degree of nonperfusion cannot be estimated due to significant retinal hemorrhage. The etiology of decreased vision in RVO is multifactorial and includes cystoid macular edema, retinal ischemia, retinal hemorrhage, vitreous hemorrhage, and neovascular glaucoma. Long-term complications include macular edema, retinal neovascularization, vitreous hemorrhage, and retinal detachment. Early and prompt
treatment of macular edema may consist of intravitreal anti-VEGF or steroid therapy in an effort to improve visual acuity. BRVO typically occurs at arteriovenous crossings where the artery and vein share an adventitial sheath (Figure 3). The artery has been observed to cross the vein anteriorly in 98% to 99% of BRVOs, compared with approximately 60% to 70% of unaffected arteriovenous crossings. This is hypothesized to occur due to thickening of the overlying artery, which causes narrowing of the vein with subsequent vascular turbulence and endothelial damage contributing to venous thrombosis. In the Beaver Dam Eye Study, the superotemporal quadrant was the most commonly involved (58.1% of eyes), followed by the inferotemporal quadrant (29%) and outside of the temporal quadrants (12.9%). The greater frequency of superotemporal BRVO may occur due to the greater frequency of arteriovenous crossings in that quadrant. Patients with superotemporal quadrant BRVO also experience greater degrees of visual acuity loss relative to BRVO in other quadrants.

CRVO generally causes greater degrees of vision loss and carries a more guarded prognosis, particularly if it is ischemic. CRVO can produce dilated and tortuous vessels with intraretinal hemorrhages in all four quadrants, optic disc edema, and cystoid macular edema. In contrast to BRVO, in which the development of neovascular glaucoma is rare, ischemic CRVO can lead to neovascularization of the iris or anterior drainage angle with subsequent elevation in IOP within 1 month of onset or later, hence the name 90-day glaucoma. Clinical features suggestive of ischemic CRVO include initial poor visual acuity, afferent pupillary defect, anterior segment neovascularization, and reduced B-wave amplitude on electroretinogram. The CVOS examined the natural history of CRVOs over a 36-month follow-up period and found that final visual acuity largely depended on the initial visual acuity and degree of retinal perfusion.

HONE YOUR RVO IDENTIFICATION SKILLS

Recognizing the clinical features of RVO and promptly diagnosing treatable causes of visual morbidity, including macular edema and neovascularization, can result in improved clinical outcomes and, often, restoration of visual acuity. The vitreoretinal specialist can play an important role in identifying underlying systemic causes of RVO in young patients and in those with bilateral symptoms. Emerging technologies such as optical coherence tomography angiography may allow better classification of macular perfusion in acute RVO and identify factors predictive of the possibility of visual improvement and the duration of therapy for treatment of macular edema.

THOMAS JENKINS, MD
Vitreoretinal Surgery Fellow, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania

tom.lee.jenkins@gmail.com

Financial disclosure: None

MICHAEL A. KLUFAS, MD
Vitreoretinal Surgeon, Mid Atlantic Retina, Wills Eye Hospital, and Assistant Professor of Ophthalmology, Thomas Jefferson University, both in Philadelphia, Pennsylvania

Retina Chief, Eyetube.net

mklufas@gmail.com

Financial disclosure: Consultant (Allergan); Scientific Advisory Board (Genentech)

DANIEL SU, MD
Vitreoretinal Surgery Fellow, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania

dsu114@gmail.com

Financial disclosure: None